Market Place
Sourcing Support
Timber Pharma Updates TMB-001 Development For Congenital Ichthyosis
21 Aug 2024 //
BUSINESSWIRE
Timber Pharmaceuticals Presents Late-Breaking Preliminary Results of TMB-001
10 Mar 2024 //
BUSINESSWIRE
NYSE American to Suspend Trading Immediately in Timber Pharma
29 Nov 2023 //
BUSINESSWIRE
Timber Announces Commencement of NYSE American Delisting Proceedings
29 Nov 2023 //
GLOBENEWSWIRE
Timber Receives Court Approval of All “First Day” Motions to Support Operations
28 Nov 2023 //
GLOBENEWSWIRE
Timber Announces NYSE Acceptance of Plan to Regain Listing Compliance
18 Sep 2023 //
GLOBENEWSWIRE
Leo Pharma spending $14M upfront to acquire Timber
21 Aug 2023 //
ENDPTS
Timber Pharmaceuticals Discloses Communication From NYSE American
03 Jul 2023 //
GLOBENEWSWIRE
Timber to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001
20 Jun 2023 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
05 Jun 2023 //
GLOBENEWSWIRE
Timber Pharmaceuticals Provides Business Update & Announces 1Q 2023 FYR
15 May 2023 //
GLOBENEWSWIRE
Timber Provides Business Update and Announces 4Q & Full Year 2022 Result
31 Mar 2023 //
GLOBENEWSWIRE
Timber Announces Publication Phase 2b CONTROL study in Experimental Dermatology
20 Mar 2023 //
GLOBENEWSWIRE
Timber Receives European Orphan Drug Designation for TMB-001
24 Feb 2023 //
GLOBENEWSWIRE
Timber to Host Investor Business Briefing: Milestone Achievements
14 Dec 2022 //
GLOBENEWSWIRE
Timber Pharma Regains Compliance with NYSE American Continued Listing Standards
09 Dec 2022 //
GLOBENEWSWIRE
Timber Pharma Provides Business Update and Announces 3Q2022 FYR
14 Nov 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split
08 Nov 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Halt of Common Stock Trading
03 Nov 2022 //
GLOBENEWSWIRE
Timber Receives European Orphan Designation for Recessive Congenital Ichthyosis
25 Oct 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering
03 Oct 2022 //
GLOBENEWSWIRE
Timber Receives Positive Opinion on Orphan Designation fromEMAfor TMB-001
14 Sep 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results
29 Aug 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Notification of NYSE American Continued
29 Aug 2022 //
GLOBENEWSWIRE
Timber Announces Publication of Results from Phase 2b Study of MB-001
26 Aug 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Provides Business Update & Announces 2Q 2022 FY Results
12 Aug 2022 //
PRESS RELEASE
Timber Pharmaceuticals Provides Business Update and Announces Q2 2022 Rusult
11 Aug 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering
08 Aug 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
04 Aug 2022 //
GLOBENEWSWIRE
Timber Pharma Begins Enrollment in PIII ASCEND Trial of TMB-001
23 Jun 2022 //
GLOBENEWSWIRE
Timber Pharma Receives FDA BTD for TMB-001 for Congenital Ichthyosis
31 May 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Timber Pharma Reports Fourth Quarter and Year End 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Late-Breaking Presentation at AAD
25 Mar 2022 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Closing of Exercise of Underwriter’s Option
09 Nov 2021 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Closing of $15 Million Public Offering
05 Nov 2021 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Proposed Public Offering
02 Nov 2021 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b of TMB-001
24 Aug 2021 //
GLOBENEWSWIRE
Timber Receives Decision to Grant Japanese Patent for Lead Asset TMB-001
28 Apr 2021 //
GLOBENEWSWIRE
Timber ’ Development Partner, AFT, Enters into Licensing Agreement
17 Mar 2021 //
PRESS RELEASE
Timber Announces 50% Enrollment in Ph 2b CONTROL Study in Congenital Ichthyosis
15 Mar 2021 //
GLOBENEWSWIRE
Timber Receives Notice of Allowance from U.S. Patent Asset TMB-001
15 Dec 2020 //
GLOBENEWSWIRE
Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders
20 Nov 2020 //
BIOSPACE
Timber Pharmaceuticals Receives Allowance from U.S. Patent for BPX-01 and BPX-04
15 Sep 2020 //
PRESS RELEASE
Timber Announces European Patent Office Intends to Grant for BPX-01 and BPX-04
22 Jul 2020 //
GLOBENEWSWIRE
Timber Announces All CONTROL Study Sites Open and Enrolling Patients
01 Jul 2020 //
GLOBENEWSWIRE
Timber Announces Appointment of Dr. Gianluca Pirozzi and Edward J. Sitar
04 Jun 2020 //
GLOBENEWSWIRE
Timber Pharmaceuticals Announces Merger Closing
18 May 2020 //
PRNEWSWIRE
BioPharmX Corporation Urges Stockholders to Vote Now on Merger with Timber
08 May 2020 //
PR NEWSWIRE
Timber Pharmaceuticals Announces Award of Second Tranche of FDA
06 Apr 2020 //
PR NEWSWIRE
